Search
Harvesting Knowledge: A Summit on Multiple Myeloma
This clinically focused program is designed to sharpen decision-making across the multiple myeloma continuum. Together with expert faculty and peers, you’ll:
Expect interactive cases, practical algorithms, and candid “what I would do tomorrow” discussions that you can immediately apply in your practice.
CLICK HERE to register for this year’s program.
100% off discount code: MMSummit100
We hope you’ll join us in Napa for this important regional gathering. Your participation would help strengthen collaboration and elevate care for patients throughout Northern California.
If you have any questions, please reach out to Shelby.abuhatzira@ucsf.edu
Hematologic Malignancies Update 2026 is a two-day meeting provides hematology and oncology clinicians, nurses, nurse practitioners and physician assistants with an overview of the most recent advances in the treatment of various hematologic malignancies.
Invited speakers choose exciting and relevant topics and discuss their clinical relevance to the hematology and oncology practice. Check out the AGENDA by clicking here!
At ANCO, we strive to foster meaningful connections and facilitate valuable interactions among participants at our meetings. To ensure a fair distribution of attendance and provide an opportunity for various stakeholders to participate and engage with the cancer care community at large, industry registrations for our meetings are intentionally limited.Industry Registrations are limited to a maximum of three representatives per company, from companies who are not exhibiting at the meeting, with a maximum of 15 companies.
This policy is contingent upon meeting registrations and venue capacity. If we do have additional space, we will accept more representatives.
How does the ANCO Industry Registration waitlist approval process work?
The Stanford Blood and Marrow Transplantation and Cellular Therapy Symposium is a two-day hybrid educational activity designed to address the evolving landscape of hematopoietic cell transplantation (HCT) and cellular therapies. As the number of eligible patients and range of disease indications continue to expand, and as supportive care requirements grow increasingly complex, there is a critical need for ongoing education among healthcare providers who refer, manage, and care for these patients before, during, and after therapy.
This symposium will provide a comprehensive review of state-of-the-art transplant and cellular therapy approaches for hematologic malignancies and select non-hematologic diseases. Faculty experts will highlight advances in treatment strategies, emerging research, and best practices in supportive care, equipping participants with the knowledge and tools to optimize patient outcomes across the continuum of care.
For more information, click HERE.
This lunch is for all ANCO and MOASC MD, Fellows, and Prospective MD and Fellow Members who are attending the ASCO Annual Meeting. This meeting is for practitioners only; industry representatives may not attend.
Lunch will be served from 11:30am - 1:30pm at the Hyatt Regency McCormick Place in the Regency CD room. Come by whenever you can!
This is not an official event of the 2026 ASCO Annual Meeting. It is not sponsored, endorsed, or accredited by ASCO or Conquer Cancer®, the ASCO Foundation. Please let us know if you plan to attend by Friday, May 22nd.
ANCO’s ASCO26 Highlights will summarize the major research and treatment advancements presented at this year’s ASCO26 Annual Meeting.
Please note, this meeting is not in affiliation in any way with ASCO.
The program will focus on developmental therapeutics, breast, gastrointestinal, genitourinary, head and neck, gynecologic, lung, hematologic malignancies, sarcoma, as well as, melanoma, and end with a panel discussion.
The faculty will place these developments in context as to their immediate clinical utility.
Registration will open in late spring 2026.
Industry Registration is not open yet. Please read below to understand ANCO's industry registraiton waitlist process:
Clinical trials are the engine of progress in oncology, offering the most promising potential therapies and, often, the treatment of choice for cancer patients. However, navigating the landscape of trial enrollment—especially for genitourinary malignancies—requires a specialized, collaborative, and patient-centered approach that is rarely incorporated in standard continuing medical education.
We invite you to join us for an innovative one-day educational meeting that bridges this critical gap. This forum convenes leading academic and community clinicians and researchers to enhance collaboration, share cutting-edge science, and strategize on best practices for clinical trial participation in kidney, bladder, and prostate cancer.
Registration will open in spring 2026.
What is ANCO’s Industry Registration policy?
Precision oncology promises to improve the outcomes of patients through broad molecular diagnostic profiling and individualized treatment recommendations. Recent FDA approvals of new cancer treatments that are based on molecular tumor features and not disease type underscore the relevance of this approach.
However, the landscape of available diagnostic technologies and targeted drugs is rapidly changing, making it extremely difficult for practicing oncologists and related professionals to stay up to date and to offer their patients the best molecular diagnostic approach possible. By attending this meeting, clinicians will be informed on cutting edge technologies and their optimal clinical application.
Apply to Become a Member
4225 Solano Ave, #764 Napa, CA 94558 Phone (415) 472-3960
Association of Northern California Oncologists © 2025 | Privacy Policy | Disclaimer